10-Q/A: Shuttle Pharmaceuticals Restates Financials After Auditor Issues, Plans Capital Raise

Shuttle Pharmaceuticals Holdings, Inc. has restated its financial statements for 2022 and 2023 due to accounting errors identified after its former auditor faced a cease-and-desist order from the SEC, and is now planning a capital raise to fund operations and clinical trials.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. has restated its financial statements for the year ended December 31, 2022, the year ended December 31, 2023, and the quarterly periods included in the company's annual report for the year ended December 31, 2023, and the quarterly report for the period ended March 31, 2024.
• The restatement was triggered by a cease-and-desist order issued by the SEC against the company's former auditor, B.F. Borgers CPA PC.
• The company identified several accounting errors, including issues with stock compensation, convertible preferred stock, notes payable, and initial public offering costs.
• The company's net loss for the three months ended March 31, 2024, was approximately $1.7 million, with no revenue.
• As of March 31, 2024, the company had working capital of approximately $2.9 million.
• The company is planning a capital raise to fund operations and clinical trials, as existing resources are not expected to be sufficient for the next twelve months.
• A 1-for-8 reverse stock split was implemented on August 13, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
• The company is developing Ropidoxuridine, a drug used with radiation therapy to sensitize cancer cells, and is preparing for a Phase II clinical trial.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financials, material weaknesses in internal controls, default on a convertible note, and the need for a capital raise. While there are some positive developments, the overall financial health and operational challenges outweigh them.

Positives

• The company has completed the manufacturing of the active pharmaceutical ingredient for Ropidoxuridine.
• The company has received FDA approval to begin the clinical trial for Ropidoxuridine.
• The company has secured a waiver from the investor of a convertible note after a default.
• The company is actively pursuing additional funding through a capital raise and a SBIR grant.

Negatives

• The company has incurred losses since inception and has a net loss of approximately $1.7 million for the three months ended March 31, 2024.
• The company's existing cash resources are not expected to be sufficient to fund operations and clinical trials for the next twelve months.
• The company's financial statements for 2022 and 2023 required restatement due to accounting errors.
• The company defaulted on a convertible note, requiring a waiver and payment of $0.6 million.
• The company's disclosure controls and procedures were deemed ineffective as of March 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company's clinical trials may encounter problems that could cause delays or suspensions.
• The company's patents may be challenged, invalidated, or circumvented.
• The company's disclosure controls and procedures were deemed ineffective as of March 31, 2024.
• The company has a history of losses and may not achieve profitability.
• The company is subject to extensive regulation by governmental authorities.

Future Outlook

The company is planning a capital raise to fund operations and clinical trials, and may pursue additional bridge financing. The company expects to commence its Phase II clinical study in the second quarter of 2024.

Management Comments

• Management concluded that the company's disclosure controls and procedures were ineffective as of March 31, 2024.
• Management is committed to maintaining a strong internal control environment and is implementing additional measures to address identified material weaknesses.
• Management believes the company remains on track to commence its Phase II clinical study in the second quarter of 2024.

Industry Context

The company is operating in the pharmaceutical industry, specifically focused on developing cancer therapies. The company's approach involves using radiation therapy in combination with novel drugs to improve patient outcomes. This is a competitive space with many companies developing similar therapies.

Comparison to Industry Standards

• Shuttle Pharmaceuticals is a development-stage company, so direct comparisons to established pharmaceutical companies are difficult.
• The company's financial metrics, such as net loss and cash burn, are typical for a company at this stage of development.
• The restatement of financials due to auditor issues is a significant concern and is not typical for companies with robust internal controls.
• The company's reliance on external funding is common for biotech companies, but the need for a capital raise due to insufficient funds is a risk.
• The company's Phase II clinical trial is a key milestone, and its success will be critical for future growth.
• Comparable companies in the biotech space include those focused on cancer therapeutics, such as companies developing radiation sensitizers or HDAC inhibitors, but specific comparisons would require more detailed information on their clinical trial progress and financial status.

Management Changes

Corporate Governance

Legal Proceedings

• Currently, there are no legal proceedings pending or threatened against the company.

Related Party Transactions

• The company has a manufacturing agreement with TCG GreenChem, Inc., where one of the company's independent directors is CEO and CSO.

Stakeholder Impact

• Shareholders are impacted by the restatement of financials and the need for a capital raise.
• Employees are impacted by the company's financial challenges and the need for cost-cutting measures.
• Customers (potential patients) are impacted by the company's ability to bring its drug candidates to market.
• Suppliers are impacted by the company's ability to pay for goods and services.
• Creditors are impacted by the company's financial challenges and the risk of default.

Next Steps

• The company will complete the Re-audit of its financial statements.
• The company will file a registration statement on Form S-1 to raise additional capital.
• The company will commence its Phase II clinical study of Ropidoxuridine.
• The company will continue to implement measures to remediate material weaknesses in internal controls.

Key Dates

Keywords

restatement, financial statements, capital raise, Ropidoxuridine, clinical trial, reverse stock split, convertible note, accounting errors, auditor, SEC, disclosure controls, material weakness, derivative liabilities, going concern